![Alliance News](https://static.lse.co.uk/images/news-logos/alliance-news-logo.png)
Hutchmed begins phase one study for potential tumour treatment
Hutchmed begins phase one study for potential tumour treatment
Read moreWed, 02nd Apr 2014 08:48
Hutchmed begins phase one study for potential tumour treatment
Read moreTOP NEWS: Retailer ASOS now to be seen on London Main Market
Read moreHutchmed gains breakthrough therapy designation in China for HMPL-523
Read moreHutchmed begins phase one study for potential cancer treatment
Read moreHutchmed completes patient enrolment for cancer drug study
Read more(Sharecast News) - Hutchmed China announced on Friday that, following negotiations with the China National Healthcare Security Administration (NHSA), from 1 January the updated National Reimbursement Drug List (NRDL) will continue to include 'Elunate', or fruquintinib, and would now include 'Sulanda', or surufatinib.
Read moreTwo Hutchmed drugs included on China's state approved medicines list
Read moreHutchmed China shares rise on Orphathys and Tagrisso Phase 3 study
Read moreTOP NEWS: Astra transfers drug rights to Covis in USD270 million deal
Read moreIN BRIEF: Hutchmed begins phase 3 trial of thrombocytopenia drug
Read moreHutchmed China sells joint venture stake for USD169 million
Read moreHutchmed starts drug combination trial for neuroendocrine tumours
Read moreHutchmed starts Japan trial for surufatinib in neuroendocrine tumors
Read moreHutchmed China's amdizalisib secures breakthrough therapy designation
Read moreHutchmed, Astra launch drug combination trial to treat lung cancer
Read more